BLIS TechnologiesNZSE:BLT Gross Margin % is 71.51% as of Mar. 2026, which is 8% below its 10-year median of 78.01. The stock has 4 warning signs investors should review. Among 732 Biotechnology companies, BLIS Technologies ranks better than 58.74% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
BLIS Technologies had a gross margin of 71.51% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
BLIS Technologies Gross Margin % Related Terms
BLIS Technologies Gross Margin % Historical Data
* Premium members only.
The historical data trend for BLIS Technologies's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NZSE:BLT vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, BLIS Technologies's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BLIS Technologies Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BLIS Technologies's Gross Margin % distribution charts can be found below:
* The bar in red indicates where BLIS Technologies's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
BLIS Technologies (NZSE:BLT) has a Gross Margin % of 71.51% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on BLIS Technologies and its competitors. This is near median its historical median of 78.01. Over the past decade, BLIS Technologies' Gross Margin % has ranged from 69.16 to 81.80. According to the industry distribution chart, BLIS Technologies ranks #302 out of 732 companies in the Biotechnology industry, placing it in the top 41.3%.
Is BLIS Technologies' Gross Margin % too high?
BLIS Technologies' current Gross Margin % of 71.51% is near median its 10-year median of 78.01. Over the past 10 years, this metric has ranged from a low of 69.16 to a high of 81.80. The Biotechnology industry median Gross Margin % is 60.91. BLIS Technologies' value of 71.51% is 17.4% above this industry median. Based on the distribution chart, BLIS Technologies ranks #302 out of 732 companies in the Biotechnology industry, which is above the industry midpoint.
How does BLIS Technologies' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BLIS Technologies ranks #302 out of 732 companies for Gross Margin %. This puts BLIS Technologies in the upper half of its industry. The industry median Gross Margin % is 60.91. BLIS Technologies' value of 71.51% is 17.4% above this benchmark. Historically, BLIS Technologies' own Gross Margin % has ranged from 69.16 to 81.80 over the past decade. While the company's 10-year median is 78.01 vs. the industry median of 60.91, BLIS Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BLIS Technologies's current Gross Margin % of 71.51% is 17.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on BLIS Technologies and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BLIS Technologies's current Gross Margin % is 71.51%, which is near median its own 10-year median of 78.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLIS Technologies stock overvalued right now?
Based on GuruFocus' analysis, BLIS Technologies (NZSE:BLT) is currently considered Modestly Undervalued. The stock's GF Value™ is NZ$0.02, compared to a current price of NZ$0.02 — trading 20% below its estimated fair value. The current Gross Margin % is 71.51%, which is near median its 10-year median of 78.01 and 17.4% above the Biotechnology industry median of 60.91. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For BLIS Technologies (NZSE:BLT), the current Gross Margin % is 71.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BLIS Technologies Ltd is engaged in developing oral probiotics. The company markets strains of probiotic bacteria BLIS K12, BLIS Q24, and BLIS M18, which occur naturally in the oral cavity. Its product portfolio consists of probiotic serum, Teeth and gums lozenge, fresh breath lozenge, and immune lozenge. Geographically, the company derives a majority of its revenue from North America. The company also generates a small portion of revenue from Non-core business, which includes grants and interest revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NZSE:BLT has been successfully added to your 